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Plain English summary: Health technology appraisal involves reviewing the findings
from clinical trials and economic data to produce guidance on how health
technology should be used. This task is carried out by appraisal committees in NICE.
One of the several ways in which patients can feed their views into these
committees is via a written patient statement. We asked nine committee members
about what difference the information from patients makes to their decision-making.
The Committee members reported that written patient statements offer a different
perspective when reviewing the clinical and economic data. This can have a
profound impact when a committee draws conclusions based solely on the data,
which may not reflect the reality of patients’ lives. The patients’ and carers’ input
provides meaning to the data, ‘bringing the numbers to life’. It identifies if the
technology has any wider impacts than what’s been reported in the clinical trial, and
also if the trial has measured what’s important to patients. We conclude that the
written patient statement adds value to the decision-making process by helping
Committee members to make sense of the clinical and economic data-it makes
them look at the evidence ‘in a different light’. Patients’ stories are very effective in
this context, because they have the power to communicate and to challenge
Committee members’ assumptions. Understanding this difference between analysing
research evidence and drawing on patients’ insights is important in thinking about
what’s needed in a written patient statement and the best way to obtain it.
Abstract:
Background
Health technology appraisal involves reviewing clinical and economic data to inform
guidance on the use of technology. In England this task is carried out by appraisal
committees within the National Institute for Health and Care Excellence (NICE).
Patients are not committee members as they have a vested interest in the outcome,
but one of the several ways they are involved is through submitting a written
patient statement, which is considered by the committee during its deliberations.
We aimed to find out how the written patient statement adds value to the decision-
making process by exploring how it is used in practice.
Methods
Semi-structured interviews were conducted with nine members of NICE appraisal
committees. The interviews were transcribed and analysed thematically. We drew on
published evidence of the impact of patient involvement on clinical research and
our experience of supporting organisations to produce written patient statements to
analyse the findings.
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Results
Committee members reported that written patient statements offer a different
perspective when evaluating clinical and economic data. This can have a profound
impact when a committee draws conclusions based on data that may not reflect the
reality of the patient experience. Information from patients and carers also provides
context and meaning to the data, by explaining its real-life implications. It identifies wider
impacts of a technology that may not have been assessed in a clinical trial, as well as
commenting on whether what has been measured in a trial is relevant to patients. The
main barrier to using the written patient statement is the misperception that it is a form
of research ‘evidence’, when in fact it takes the form of experiential knowledge - or
insight.
Conclusions
The written patient statement adds value by aiding Committee members in their
interpretation of existing evidence – it enables them to consider this evidence ‘in a
different light’. In this context, patients’ experiential knowledge is effective because it is
subjective, emotional and anecdotal. It then has the power to communicate and to
challenge assumptions based on the data alone. Understanding this difference between
using evidence and insights has implications for the content of a written patient
statement and the approaches used to obtain it.
Keywords: Health technology assessment, Health technology appraisal, Health
technology assessment committees, Patient and public involvement, Public involvement,
Evidence
Background
Health technology appraisal is a multi-stage process with potential for patient and pub-
lic involvement at all stages. The entire process includes: setting priorities for appraisal,
scoping the questions to be addressed, carrying out an economic analysis, evaluation of
the clinical and economic research evidence (technology appraisal) and communication
of the final outcome [1–5]. In this article, we consider the value of patient and public
involvement in technology appraisal, where consideration is given to clinical and eco-
nomic data as well as wider legal, social and ethical issues, to inform guidance on the
use of new and existing technologies. In England this task is carried out by appraisal
committees within the National Institute for Health and Care Excellence (NICE) [6].
Within NICE, the views of patients, carers and the public are included in the appraisal
process in a number of ways. At the initial scoping stage, interested patient organisations
and charities participate in a consultation to help set the questions to be answered during
the appraisal. They can also register as stakeholders when the guidance development
starts, which enables them to be involved in later stages as described below.
At the stage of evaluating the research evidence, there are two distinct roles for the
public and/or patients. One is as a member of an appraisal committee, i.e., someone
who participates in the process. This is the role of the lay members of NICE commit-
tees. Importantly these lay members do not include patients with direct experience of
the condition under review. It can be argued that such patients should not be party to
the decision-making process, because they have a vested-interest in the outcome. For
the same reason, representatives of the manufacturers of the technology being assessed
are not included as committee members.
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However, it is recognised that because any decision will have a major impact on pa-
tients’ lives, patients and carers do have a right to have their views heard by the com-
mittee. Therefore, the registered patient groups and organisations are invited to
produce a ‘patient statement’, a written report, which is considered at the same time as
the clinical data produced by the manufacturers and economic data from health econo-
mists [7]. Expert patients and/or their representatives from the registered stakeholder
organisations are selected by NICE to attend part of the appraisal committee meeting
and can make comments on the day. They usually include someone from a patient or-
ganisation and someone with experience of the condition and the technology under re-
view. The expert patients/ representatives also produce a written summary of their
experiences, which is included in the meeting papers.
It has been argued that there is a need to seek patients’ views during the ap-
praisal, because patients can provide a real-world view of the social and psycho-
logical impacts of the use of a technology [2, 3]. They can also provide an
understanding of the ‘burden of their illness’ and their experience and expectations
of current treatments. However, there is no clarity or transparency as to how such
information influences a committee’s deliberative process. Although templates have
been produced for written patient statements, it is still unclear as to what precise
information is most useful to include and the questions asked can seem very
broad. The main conclusions to date are that this ‘evidence’ should be obtained
through qualitative research conducted by social scientists [2, 3]. On this basis, it
has also been suggested that appraisal committees should include professionals
with experience in social or humanistic sciences, to ensure rigorous methodological
analysis and an evaluation of the quality of this patient evidence, in much the same
way that clinicians and economists assess the clinical and economic data [2].
In this article, we address the question: How do the views of patients directly affected
by a new technology add value to the appraisal process? We interviewed academic,
clinical and lay members of appraisal committees to ask how they had used the written
statements from patient organisations and how this had influenced their decision-
making in practice. We have also drawn on the literature describing the impact of pa-
tient and public involvement on clinical research and our own experience of working
with patient groups to produce written patient statements for the former NHS National
Specialised Commissioning Team (NSCT). We have analysed these findings to develop
a clearer understanding of the kind of information from patients that can best support
and enhance decision-making within appraisal committees.
Methods
Interviews with appraisal committee members
Semi-structured telephone interviews lasting 30–45 mins, were conducted with nine
members of NICE health technology appraisal committees in England, during February
and March 2014. We approached all thirteen members of a single committee (which
has not been identified to protect the anonymity of the interviewees). Only nine were
available to take part in the time available. Some had been members of other appraisal
committees in NICE and were able to draw on several years of experience. They came
from a range of disciplines including consultants from different areas of medicine,
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health service managers, lay members (from patient organisations and business) and
university academics working in health service research.
As NICE had only commissioned us to explore the use of written patient statements,
we focused our questions on whether and how these statements made a difference to
the committees’ decision-making and how the quality of this information might be im-
proved. With the interviewee’s permission, the interviews were recorded and tran-
scribed. The transcripts were analysed using inductive thematic analysis [8, 9], i.e., the
themes were developed from the interview data, rather than drawing on an existing
theory. The initial development of themes was carried out by KS, and discussed with
CD to develop the conclusions. We drew on our experience of public involvement in
research and experience of producing written patient statements to inform our analysis.
Five distinct themes emerged. Four related to the added-value of the written patient
statement, in terms of aiding understanding of the health condition under review, the
benefits and risks of the new technology, the wider impacts of the new technology and
the relevance of the clinical research. The fifth theme related to barriers to the use of
the written patient statement. These are discussed in turn in the combined results and
discussion section. Direct quotes are from interviews with committee members, unless
otherwise specified, and are written in italic.
Literature review
A review of the literature reporting on the impact of public involvement on research
was undertaken in 2009 [10]. The findings have been supported by three subsequent re-
views [11–13]. INVOLVE, (an organisation funded by the National Institute for Health
Research to support public involvement in NHS, public health and social care research)
has continued to review the published evidence of impact and produced an online
bibliography [14]. We drew on the evidence from these reviews, and discuss some of
the findings in conjunction with the results from the interviews.
Developing written patient statements
In 2012, TwoCan Associates (a small company specialising in promoting and support-
ing public involvement in research) were commissioned to develop two written patient
statements for the NHS NSCT to inform the work of the Advisory Group for National
Specialised Services (AGNSS), one relating to atypical hemolytic-uremic syndrome
(aHUS) and one relating to transthyretin familial amyloid polyneuropathy (TTR-FAP).
AGNSS was a committee that considered services and drugs for very rare conditions
(conditions which affect less than 500 people in the UK). NICE took over this assess-
ment of highly specialised technologies from 1 April 2013. We have drawn on this ex-
perience to inform our conclusions.
Results and discussion
General overview
In general terms, committee members reported that written patient statements offer a
very different perspective when evaluating the clinical and economic data, enabling
members to answer the question ‘What does this mean for patients?’
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When the micro-technicalities take over the discussion, it enables the chair or one of
the committee to say ‘What does the actual patient think about this? Is this really an
issue?’ (Committee member 3)
The written patient statement thus provides a counterbalance to the committee’s pro-
fessionalised views. This is similar to the experience of clinical researchers who describe
the input from involved patients as a ‘reality-check’[15].
The perspective from a committee room is quite artificial… the value of [a written
patient statement] is that it is real. It connects information about people’s lives with
the decision being made. You can miss that when you are talking about costs or trial
data or pharmacological indications… The risk of not taking this into account is that
the committee ends up going off on a tangent… (Committee member 7)
On occasion, the patients’ views have had a profound impact on decision-making
(see the example of the review of insulin-glargine below) when committee members
have drawn conclusions based on the clinical and economic data that do not reflect the
reality of the patient experience.
From time to time, what patients have said has been an absolute lightbulb moment,
a fantastic insight that you wouldn’t get from anywhere else, but that is
occasional.(Committee member 4)
More specifically, the written patient statement has provided patients’ and also carers’
perspectives on:
 The nature of the condition i.e., explaining what the clinical description means in
real life
 The clinical benefits and side-effects of the new technology i.e., what the ‘numbers’
mean in real life
 The wider impacts of the new technology i.e., the impacts that matter to patients and
carers that may not have been captured through the clinical and economic research
 The relevance of the research findings i.e., whether the clinical trials have assessed
what matters to patients and carers
These issues will now be discussed in turn, followed by consideration of the barriers
to making use of the information from patients.
The nature of the health condition under review
The written patient statement often provides valuable background information that en-
ables the committee to put the evidence into a real-life context. It includes details of:
 the natural history of the condition-when it starts in life, how it changes over time,
and whether it is life-threatening
 the range of ways that patients are affected and the different ways that different
groups of patients may be affected - in terms of impacts on health
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 the ways in which the lives of patients, family members, partners and carers are
affected-the physical, psychological, emotional, social and financial impacts
 how the condition affects patients’ and carers’ quality of life
 the positive and negative impacts of treatments that are currently available
Patients and carers are able to provide unique insights based on their direct experi-
ence of a condition, which are distinct from other expert views, as one committee
member described:
Even clinicians who are familiar with the condition-do they really know what the lives
of people are like? Even for them the [written patient statement] can be an eye-
opener. (Committee member 1)
By providing this information in their own words, the patients also aid the commit-
tee’s understanding of clinical descriptions of a health condition. For example, a clinical
description of amyloidosis might state that the condition results in ‘rapidly-progressing
peripheral neuropathy’. What this means in real-life becomes much clearer when de-
scribed by a patient as follows:
I’ve lost sensation in my fingers which means I can’t use a keyboard. I’ve found I can
use an iPad, but am reluctant to spend all that money when I can’t be sure I’ll still
be able to use it in six months’ time. (Quote from a patient interviewed for a written
patient statement for AGNSS)
The clinical benefits and side-effects of the new technology
Committee members reported that the information from patients helps to translate the
quantitative, clinical data into real-life experience. This is useful in assessing whether
the reported benefits are significant and valued by patients, and helps with ‘making
sense of the numbers’.
It gives some substance to what would otherwise just be quality of life numbers.
(Committee member 5)
In another example, where the clinical impact of a new technology was described as
an increase in visual acuity, based on scores from reading a Snellen chart, the patients
explained that this level of improvement meant, for example, that they were then able
to see well enough to drive, and therefore able to return to work.
It can also be important to look at these benefits from the patients’ perspective, be-
cause patients may place much greater value on small improvements, than someone in
good health ‘looking in from the outside’. Making judgements about the value of small
improvements was recognised by some committee members as a challenging aspect of
the appraisal process.
Without the patient’s voice, it’s easier to be a little bit more dismissive if you’re
looking at clinical data… rather than hearing what effect it had on the individual
patient. (Committee member 2)
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Committee members also valued hearing the patients’ views on the side-effects of
new technologies. This had sometimes challenged the committee’s assumptions about
their impact.
There was a patient who said ‘I’m taking this drug, but I’ve had to stop it for a couple
of days, because it gives me such bad diarrhoea that I wouldn’t have been able to
come to this meeting…’ It was that insight - on the page they [the manufacturers] say
‘Side-effects-X% of people get gastrointestinal problems’, but actually that illustration
was wow, this is much more important than it appears on a list of adverse effects.
(Committee member 4)
The wider impacts of the new technology
The written patient statement provides information about impacts that are not in-
cluded in the clinical and economic data, in particular, impacts beyond clinical out-
comes, and impacts on people other than the patient.
If, for the carer, the treatment means for example they can sleep all night-that would
be an incredible step forward-but that wouldn’t have been measured. (Committee
member 1)
In another example, patients provided a different perspective on the clinical data,
which profoundly changed the Committee’s thinking:
We were considering insulin-glargine and the evidence showed that using conventional
insulin and insulin-glargine had the same effects on HbA1c [a biomarker for diabetes
control] but the glargine cost loads more, but what the committee heard from the pa-
tients was that if you have any tendency towards hypoglycaemic events, which can hap-
pen with standard insulin, then you literally went to bed every night scared you weren’t
going to wake up as a consequence of having a hypo. So people wouldn’t take their insu-
lin and their base level of HbA1c was much higher. So the committee asked for work to
be done to survey patients to see how common this behavioural response was, and what
impact the higher HbA1c levels would have on survival. Glargine did not result in hypos
so had less behavioural impacts-you could take it and run yourself at the appropriate
HbA1c level. With the additional evidence, the committee was convinced that a propor-
tion of patients would respond better that way. (Committee member 5)
The relevance of the research findings
For committee members, it is important to understand whether a new technology ad-
dresses what patients consider to be a priority symptom. This is unlikely to be revealed
in trial data. Importantly, this information can only come from the patients themselves,
as clinicians may hold different opinions.
On occasions there’s a discrepancy between the clinicians and the patients… what
clinicians think is important and what patients think is important is not always the
same. Sometimes what clinicians think is terribly important, patients will say ‘I’ve
learned to live with that’. (Committee member 4)
Staley and Doherty Research Involvement and Engagement  (2016) 2:4 Page 7 of 12
Such discrepancies have also been reported in clinical research, where patients’ prior-
ities for research on their condition have been shown to be different to those of clini-
cians and those of researchers [15–19].
Patients are also in the unique position of being able to comment on whether the
outcome measures used in clinical trials actually measure what matters to them. Sev-
eral studies have identified discrepancies between the treatment outcomes that patients
prefer, and those that clinicians believe patients prefer [20–25]. An appraisal of a new
treatment for psoriasis revealed such a distinction. In their statement, the patients com-
mented that clinical benefit is often measured in terms of a % reduction in the areas of
skin affected by psoriasis, but what matters to them is whether the psoriasis is visible
or present on their joints, as this has much more of an impact on their daily lives. As
one Committee member commented:
What it can do [the written patient statement] is make you realise that what’s been
measured may not get to the heart of what’s going on. (Committee member 5)
Barriers to making use of the information from patients
Although committee members were aware of the potential value of written patient
statements as illustrated by their examples above, all but one expressed concerns about
incorporating the patient perspective into the decision-making process-on the basis
that the patients’ information does not appear to constitute ‘robust evidence’ (see
Table 1). There is a tendency to try to weigh-up the patients’ views against the clinical
and economic data, which proves difficult.
We need objective evidence presented to us, that we can be reassured will accurately
tell us what is going on for these patients… part of the problem here [with the written
patient statement] is a concern about quality. (Committee member 7)
It’s really important to hear the stories from real patients, but it’s not good enough as
evidence. (Committee member 8)
The challenge is that there’s an ill person who will be pulling on your heartstrings
possibly, and that is set against this more objective evidence. (Committee member 9)
However, there was also some recognition that the written patient statement offers a
different kind of knowledge or insight, one that can be valued in its own right.
Table 1 The differences between ‘evidence’ and ‘insights’ from patients
The nature of ‘evidence’ The nature of experiential knowledge
• Data obtained through systematic enquiry • Knowledge gained through experience - insight
• Objective • Subjective
• Rational • Emotional
• Written in scientific and technical language • Written in the patients’ own words
• Mostly quantitative - statistics • Mostly qualitative - stories
Apples Pears
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It’s not about robustness-this is information about how half a dozen people feel. We
need to see them [the written patient statement and the clinical and economic data]
as apples and pears. Part of the issue about judgement at this [national] level, is to
be able to make judgements between apples and pears-not just reducing everything to
apples. (Committee member 1)
Conclusion
In undertaking this review of how written patient statements are used by committee
members during technology appraisal, we have increased our understanding of how
this information adds value in practice. We conclude that it provides a very different
form of knowledge to experimental data and functions in a very different way to
‘evidence’.
How written patient statements are used in practice
The written patient statement adds value to the committee’s decision-making
process by providing the real-life context to the use of the technology and by
‘bringing the numbers to life’. Perhaps most importantly it acts to challenge as-
sumptions that others make based on the clinical and economic data alone. We
therefore conclude that the role of the written patient statement is to aid the
Committee’s interpretation and understanding of the ‘evidence’. The Committee
members have very different backgrounds, and approach this task in different ways.
However, they all have one thing in common-none has direct experience of the
condition under review. The written patient statement provides this missing per-
spective as shown in Fig. 1. Only patients are able to draw on their direct experi-
ence to evaluate the clinical research evidence.
The information from patients does not therefore need to function as ‘evidence’ in
the same way as the clinical and economic data. It does not to sit alongside this evi-
dence. Nor should it be weighed up against this evidence. It is better understood as an
interpretive tool to aid Committee members in their evaluation and deliberation of the
existing clinical and economic data-it enables them to consider this evidence ‘in a dif-
ferent light’.
Patients’ & carers’ 
insights
Evidence           Interpretation            Discussion          Decision 
Lay members 
Academics        Committee members
Clinicians 
}
Fig. 1 Where do the patients’ insights add value to the decision-making process?
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The written patient statement provides experiential knowledge or insight
‘Evidence’ within the context of evidence-based medicine takes a particular form - ex-
perimental, objective and often quantitative data. The information obtained from pa-
tients is very different in nature (see Table 1). Rather than data, it is knowledge gained
through experience i.e., insight or wisdom. It is therefore subjective, emotional and
often written in the patients’ own words (anecdotal). When judged by the standards re-
quired of ‘evidence’ the written patient statement tends to fare poorly, which as one
Committee member described is like ‘comparing apples and pears’.
However, in the context of functioning as an aid to understanding and interpreting
the clinical and economic data, the experiential knowledge of patients works extremely
well. In particular, patients’ ‘stories’ have the power to communicate and challenge
Committee members’ assumptions. For example, in the review of insulin-glargine (de-
scribed above) a patient saying ‘I don’t take my insulin at night in case I don’t wake
up in the morning’ brought the Committee’s attention to an important gap in the
clinical and economic data, in a way that a professionalised statement about ‘non-ad-
herence to treatment’ might not have done. For this reason, we conclude that if we
aim to increase the ‘robustness’ of the written patient statement, in effect turning it
into a piece of qualitative research, we would be in danger of reducing its value. If
professionals without direct experience of a condition first interpret what patients
say, and then report the findings using technical ‘jargon’, this professionalised account
may distort the original meaning and it may lose its power to challenge and influence.
For this reason, we suggest that the process of developing the written patient state-
ment might be better understood as a consultation to obtain patients’ and carers’ per-
spectives (informed by their direct experience) on the significance and relevance of
existing clinical data, rather than a piece of research to produce additional ‘evidence’
of the patients’ experience.
It is of note, that although we asked interviewees about their use of the written patient
statement from patient organisations, when reflecting on examples of where the patients’
contributions had made a profound impact on the decision-making process, some commit-
tee members referred back to verbal comments made by individual expert patients attend-
ing an appraisal meeting. This may be because experiential knowledge or insights have
greater resonance and impact when heard directly from the individual concerned. i.e., when
heard ‘from the horse’s mouth’. This observation merits further exploration, as there are im-
portant implications for the selection and role of patient experts. The findings from this
project may also be of relevance to the written summaries produced by these experts.
What are the implications for practice?
To date, the value of the written patient statement has been understood as providing
an understanding of patients’ experience of a health condition and their use of current
treatments. Our analysis shows it has the potential to do much more than that. It also
provides insights into the significance and relevance of the clinical and economic data.
We conclude that a written patient statement needs to broaden from describing a con-
dition and considering the wider social and psychological issues, to also include pa-
tients’ and carers’ views on the existing clinical data. This means asking patients and
carers questions such as:
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 Does the new technology address a symptom/issue that’s a priority?
 What do the reported clinical benefits mean in real-life for patients and carers?
What are the wider impacts?
 How ‘tolerable’ are the side-effects?
 Has this clinical trial measured what matters to patients and carers?
Furthermore, there has been little clarity to date on how the written patient state-
ment should be used within the context of health technology appraisal. Although the
results of this project are limited by the fact that we only interviewed a small number
of appraisal committee members, we conclude that all stakeholders involved may bene-
fit from a greater awareness of the way in which patients’ and carers’ experiential know-
ledge can add value to the interpretation stage of the decision-making process. This
may help appraisal committee members to make better use of the information, by
countering any misperceptions that this information should take the form of research
evidence. It may also provide greater clarity to patient organisations as to which aspects
of the patients’ experience and insights are most valuable for the committee to hear
about and which are likely to usefully inform the committee’s deliberations. Further re-
search is required to develop clear guidance on the development and use of written pa-
tient statements, both for appraisal committee members and patient organisations.
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